Investors never know what to expect for LCA-Vision
What analysts say:
- Buy, sell, or hold?: Analysts don't like LCA-Vision as much as competitor Hanger Orthopedic Group overall. Four out of four analysts rate Hanger Orthopedic Group a buy compared to zero of one for LCA-Vision. LCA-Vision's rating hasn't changed over the past three months.
- Revenue Forecasts: On average, analysts predict $22.5 million in revenue this quarter. That would represent a rise of 16.8% from the year-ago quarter.
- Wall Street Earnings Expectations: The average analyst estimate is a loss of $0.10 per share.
What our community says:
CAPS All-Stars are strongly backing the stock, with 95.3% awarding it an "outperform" rating. The community at large concurs with the All-Stars, with 90.5% granting it a rating of "outperform." Fools feel positively about LCA-Vision and haven't been shy with their opinions lately, logging 219 posts in the past 30 days. Despite the majority sentiment in favor of LCA-Vision, the stock has a middling CAPS rating of three out of five stars.
Now let's look at how efficient management is at running the business. Margins illustrate how efficiently a company captures portions of sales dollars. LCA-Vision has seen increasing operating margins year-over-year for the last four quarters. Operating margins reflect the total sales revenue that the company retains after costs. Here is how LCA-Vision has been doing for the last four quarters:
One final thing: If you want to keep tabs on LCA-Vision movements, and for more analysis on the company, make sure you add it to your Watchlist.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.